Adverse events should be reported.
Healthcare professionals are asked to report any suspected adverse events via:
HPRA Pharmacovigilance
Tel: | +353 1 6497671 |
Fax: | +353 1 6762517 |
Website: | |
Email: |
▼ This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product.
Adverse events should also be reported to Janssen-Cilag Ltd on 0044 1494 567447 or at dsafety@its.jnj.com.
Content Date of Preparation: March 2022
Item Code: CP-302812